Sekisui Chemical Co., Ltd. · TSE:4204
Sekisui Chemical — FY2025 Earnings Presentation
50 slides from Sekisui Chemical's earnings presentation, Apr 28, 2026
Slide 1: Presentation of Financial Results and the FY2026 Management Plan
SEKISUI CHEMICAL CO., LTD. For FY2025, ended March 31, 2026 Presentation of Financial Results and the FY2026 Management Plan Ikusuke Shimizu President and CEO April 28, 2026
Slide 2: Main Points of Today’s Presentation
Main Points of Today’s Presentation ★：Record high Compared Difference Difference from the Compared FY2025 Medium-Term FY2026 with from Forecasts Management Plan with Results Plan (JPY billion) FY2024 (January 2025) (May 2023) FY2025 Net sales ★ 1,309.3 +11.5 -18.6 -100.7 ★ 1,408.4 +99.1 Operating pr
Slide 3: Returns to Shareholders
Returns to Shareholders ▌ Achieve a sixteenth consecutive FY of dividend growth; continue to actively return profits to shareholders in FY2026 Medium-term Management Plan（2023-2025） Returns to Shareholders Track Record (JPY billion) Return policy Acquisition of treasury shares Dividend payout ratio
Slide 4: Launch of the Film-Type Perovskite Solar Cell Business
Launch of the Film-Type Perovskite Solar Cell Business ▌ Established production technology for 1-meter-wide panels using existing production equipment while completing preparation for installation specifications targeting metal roofs; decision made to launch a film-type perovskite solar cell busines
Slide 5: FY2025 Results
FY2025 Results FY2024 FY2025 Forex rate 1H 2H 1H 2H In-house ¥155/US$ - Tatsuya Nishida assumptions ‐ ‐ ¥181/€ Results (Avg. rate for ¥153/US$ ¥166/€ ¥152/US$ ¥162/€ ¥146/US$ ¥168/€ ¥156/US$ ¥182/€ Senior Managing Executive Officer each term) Head of Business Strategy Department * Export data is sub
Slide 6: Overview of FY2025 Results
Overview of FY2025 Results ▌ Increase in net sales; fourth consecutive FY of record-high sales ▌ Decrease in operating profit; increase in ordinary profit largely on the back of the increase in foreign exchange gains; results in excess of forecasts (January 2026) ▌ Despite incurring an impairment lo
Slide 7: FY2025 Results by Segment
FY2025 Results by Segment ▌ Increase in net sales and substantial increase in operating profit in the Housing Company; while falling below forecasts (January 2026), increase in operating profit in the UIEP Company; each of the aforementioned helped offset results in other segments ▌ Other: PV* down
Slide 8: 1H & 2H FY2025 Results by Segment
1H & 2H FY2025 Results by Segment ▌ Despite the impact of sluggish market conditions in the 1H, improvement in profitability across all four segments in the 2H as the effects of various measures began to emerge ▌ Results in the Housing and UIEP companies offset decreases in operating profit in the H
Slide 9: FY2025 Results Analysis
FY2025 Results Analysis ▌ Net sales came in below forecasts (January 2026) owing to continued sluggish market conditions in Japan and overseas; decrease in operating profit with the substantial drop in sales volumes & product mix below forecasts (January 2026) ▌ Increase in both net sales and operat
Slide 10: FY2026 Plan
FY2026 Plan FY2025 FY2026 Forex rate 1H 2H 1H 2H In-house ¥155/US$ ¥155/US$ assumptions ‐ ‐ ¥183/€ ¥183/€ Results ¥146/US$ ¥156/US$ (Avg. rate for - - each term) ¥168/€ ¥182/€ * Export data is subject to in-house assumptions regarding foreign currency exchange rates. A ¥1 depreciation in the value o
Slide 11: FY2026 Plan: Overview and Returns to Shareholders
FY2026 Plan: Overview and Returns to Shareholders ▌ Increase in net sales; planning an increase in operating profit ▌ Significantly impacted by the absence of foreign exchange gains recorded in the previous year, ordinary profit forecast to decline; planning an increase in the bottom line ▌ Planning
Slide 12: Impact on the Company’s Business from Deteriorating Conditions in the Middle East
(Reference) Impact on the Company’s Business from Deteriorating Conditions in the Middle East ▌ Despite an uncertain outlook, working to strengthen initiatives aimed at minimizing impacts through self-supporting measures Assumptions and Approach ◼ The deterioration in conditions across the Middle Ea
Slide 13: Outlook for Market Conditions
Outlook for Market Conditions Number of Automobiles Manufactured (YoY) Housing・Visitors (YoY) 4Q FY2025: Slight downturn compared with forecasts (January 2026); 2H FY2025: Overall visitors below the previous year owing to a drop trends down YoY in exhibition visitors FY2026: Overall trends in line w
Slide 14: FY2026 Plan by Segment
FY2026 Plan by Segment ▌ Increase in both net sales and operating profit in each of the four segments; plans for record- high operating profit in the HPP and UIEP companies as well as on a Group-wide total basis ▌ New business (perovskite solar cell business) ▌ Other: PV down ¥5.4 billion, LB down ¥
Slide 15: 1H & 2H FY2026 Plans by Segment
1H & 2H FY2026 Plans by Segment ▌ Targeting an increase in both net sales and operating profit across all segments in the 1H and 2H ▌ Planning record high net sales and operating profit in three segments in the 1H; targeting record high operating profit across all segment in the 2H 1H FY2025 1H FY20
Slide 16: FY2026 Plan Analysis
FY2026 Plan Analysis ▌ Increase in both net sales and operating profit on the back of continued growth in high- performance and high-value-added products; forecasting a substantial increase in sales volumes & product mix ▌ Despite an increase in fixed costs, including human capital investment, plann
Slide 17: Consolidated Performance
Consolidated Performance ▌ Planning an ROE of 9.0%; continue to strengthen earning power and improve capital efficiency (JPY billion) EBITDA 133.4 137.7 137.3 133.2 116.6 137.6 142.1 147.1 161.7 ★164.6 ★178.8 1,420.5 1,309.3 1,242.5 1,256.5 1,297.8 1,157.9 1,107.4 1,142.7 1,129.3 Net sales 1,065.8 1
Slide 18: Financial Results FY2025
Copyright® SEKISUI CHEMICAL CO., LTD Financial Results FY2025 17
Slide 19: Consolidated Companies
Consolidated Companies Number of Consolidated Companies Mar. 31, 2025 Mar. 31, 2026 Difference Consolidated Increased: 5 Subsidiaries*1 subsidiaries 145 145 Decreased: 5 Subsidiaries*2 Affiliates Increased: 0 Subsidiaries (Equity Method) 6 6 Decreased: 0 Subsidiaries *1 1Creast Co., Ltd., Sekisui Pl
Slide 20: Summary of Profit and Loss
Summary of Profit and Loss + FY2024 FY2025 Difference (JPY billion) Net sales 1,297.8 1,309.3 +11.5 Foreign exchange losses: -0.4 Gross profit 420.6 424.2 +3.6 Sekisui Kasei Co., Ltd.: +3.1 Gross profit margin 32.4% 32.4% 0% Selling, general and administrative expenses 312.7 317.7 +5.0 Foreign excha
Slide 21: Balance Sheets (Assets)
Balance Sheets (Assets) Mar.31 Inventories (B/S item) 2026 Difference Ready-built housing (products) 43.7 +10.4 Prepared land for subdivision housing 86.1 +17.0 Land under preparation Mar. 31, 2025 Mar. 31, 2026 Difference (work in process) 15.1 +5.4 (JPY billion) Housing under construction (work in
Slide 22: Balance Sheets (Liabilities & Net Assets)
Balance Sheets (Liabilities & Net Assets) (JPY billion) Mar. 31, 2025 Mar. 31, 2026 Difference Non-interest-bearing liabilities 384.6 402.0 +17.4 Interest-bearing liabilities 110.8 144.8 +34.0 Net profit: +75.2 [Net interest-bearing liabilities] [-31.8] [47.6] [+79.3] Dividends paid: -34.2 Total lia
Slide 23: Consolidated Cash Flows
Consolidated Cash Flows (JPY billion) FY2024 FY2025 Cash flows from operating activities 119.2 78.3 Cash flows from investing activities -61.5 -69.1 Cash flows from financing activities -61.2 -46.5 Net increase in cash and cash equivalents -5.5 -29.2 Cash and cash equivalents at end of period 120.9
Slide 24: Depreciation, Amortization, Capital Expenditures and EBITDA
Depreciation, Amortization, Capital Expenditures and EBITDA Goodwill and other Depreciation*1 Capital expenditures EBITDA*3 amortization*2 Differ- Differ- Differ- Differ- FY2024 FY2025 FY2024 FY2025 FY2024 FY2025 FY2024 FY2025 ence ence ence ence (JPY billion) HPP 22.3 23.5 +1.2 1.2 0.9 -0.3 26.8 32
Slide 25: Depreciation, Amortization, Capital Expenditures, Research and Development Expenditure
Depreciation, Amortization, Capital Expenditures, Research and Development Expenditure FY2026 FY2025 Difference (JPY billion) Plan Depreciation 55.9 61.8 +5.9 Goodwill and other amortization 2.2 2.0 -0.2 Capital expenditures 92.9 110.0 +17.1 EBITDA 164.6 ★178.8 +14.2 Research and development expendi
Slide 26: High Performance Plastics Company
High Performance Plastics Company Akira Asano Company President 25
Slide 27: HPP Company Performance Trends
HPP Performance Trends Company ▌ FY2025: While net sales increased on the back of such factors as steady growth in high-performance interlayer films in the Mobility field, decrease in operating profit owing to the impact of one-off expenses ▌ FY2026: Despite the considerable uncertainty surrounding
Slide 28: HPP Company FY2025 Results Analysis
HPP FY2025 Results Analysis Company ▌ Despite sluggish growth in the EV market, firm trends in interlayer films for HUDs; in addition to an upswing in aircraft demand, increase in sales volumes & product mix mainly in the Mobility field; despite an increase in net sales and decrease in operating pro
Slide 29: HPP Company Overview of FY2026 Plan
HPP Overview of FY2026 Plan Company ▌ Substantial increase in the sales volume & product mix mainly in the Mobility field and increase in net sales in each of the three segments offset the impact of higher fixed costs as associated with the accelerated pace of development; planning a substantial inc
Slide 30: HPP Company Three Strategic Fields
HPP Three Strategic Fields Company Net Sales Trends and KPIs in the Three Strategic Fields Electronics Mobility Industrial • Display market conditions projected to • Ongoing firm trends for HUDs (FY2025: 123% • Continue to capture new orders in various fields, remain firm growth* in products for HUD
Slide 31: Housing Company
Housing Company Masahide Yoshida Company President 30
Slide 32: Housing Company Performance Trends
Housing Performance Trends Company ▌ FY2025: Despite a decrease in the number of houses sold owing to the slump in new housing market conditions, increase in net sales and substantial increase in operating profit on the back of higher unit prices as a result of improvements in the product mix and gr
Slide 33: Housing Company FY2025 Results Analysis
Housing FY2025 Results Analysis Company ▌ Despite a drop in the number of houses sold in the Housing Business, higher unit prices as a result of growth in apartment buildings and high-priced detached housing contributed to the upswing in operating profit; order growth on the back of efforts to stren
Slide 34: Housing Company Overview of FY2026 Plan
Housing Overview of FY2026 Plan Company ▌ Planning an increase in both net sales and operating profit on the back of an increase in the number of houses sold as a result of efforts to strengthen the product lineup in the Housing Business as well as measures aimed at bolstering the product menu in th
Slide 35: KPIs by Business and Measures to Strengthen Profitability
Housing KPIs by Business and Measures to Strengthen Profitability Company Housing Business <Amount of Orders and the Number of (YoY) Sales strategies New Housing Orders (YoY) Buildings by Type of Construction> FY25 FY26 • Expand the Housing Company’s coverage by offering • FY2025: Amount came in abo
Slide 36: Urban Infrastructure & Environmental Products Company
Urban Infrastructure & Environmental Products Company Yoshiyuki Hirai Company President 35
Slide 37: UIEP Company Performance Trends
UIEP Performance Trends Company ▌ FY2025: Despite the effects of a prolonged slump in market conditions, recorded an increase in operating profit by maintaining margins; fourth consecutive FY of record-high operating profit ▌ FY2026: Plans for an increase in both net sales and operating profit on th
Slide 38: UIEP Company FY2025 Results Analysis
UIEP FY2025 Results Analysis Company ▌ Offset the deterioration in sales volumes & product mix attributable to the prolonged slump in housing, non-residential, as well as market conditions in India by expanding margins mainly in the domestic business and through pipeline renewal and performance mate
Slide 39: UIEP Company Overview of FY2026 Plan
UIEP Overview of FY2026 Plan Company ▌ Offset the impact of the upswing in fixed costs attributable to such factors as human capital investment and measures aimed at enhancing capabilities through a substantial increase in sales volumes and product mix mainly of pipeline renewal and performance mate
Slide 40: UIEP Company Three Strategic Fields
UIEP Three Strategic Fields Company Net sales in the Three Strategic Fields and KPI’s Building and Pipe Systems Infrastructures Composite Materials • Piping materials: Housing and non-residential markets expected to • Fire-resistant and non-flammable materials: Accelerate sales growth by expanding e
Slide 41: Medical Business
Medical Business Hiroyuki Yamashita President of SEKISUI MEDICAL CO., LTD 40
Slide 42: Medical Business Performance Trends
Medical Performance Trends Business ▌ FY2025: Decrease in both net sales and operating profit owing to the downturn in demand for priority infectious disease testing kits in the U.S. and the impact of weak market conditions in China ▌ FY2026: Despite continued harsh overseas diagnostics market condi
Slide 43: Medical Business FY2025 Results Analysis
Medical FY2025 Results Analysis Business ▌ Despite extensive efforts to control fixed costs, including the consolidation of operations in the U.S. and China, decrease in both net sales and operating profit owing to the drop in demand for priority infectious disease testing kits in the U.S. and ongoi
Slide 44: Medical Business Overview of FY2026 Plan
Medical Overview of FY2026 Plan Business ▌ While harsh diagnostics (overseas) market conditions are projected to linger, continue to promote improvements in profitability ▌ Targeting an increase in both net sales and operating income by focusing in increasing market share through the sale of new dia
Slide 45: Medical Business Overview by Business
Medical Overview by Business Business Net sales by Business and Overview of Progress Diagnostics (Japan) Diagnostics (overseas) • FY2025: Steadily captured immunology testing demand • FY2025: Substantial drop in infectious disease product demand in the U.S.; continued sluggish market conditions in C
Slide 46: This slide presentation contains forward-looking statements
This slide presentation contains forward-looking statements. These statements are based on current expectations and beliefs. However, actual results may differ from those expressed or implied due to a number of factors and uncertainties such as changes in the global economy and our business, competi
Slide 47: Housing Company Results and Plan
Housing Company Results and Plan 1. Main data in Housing business 5ｚｚｚｚｚｚｚｚｚｚｚｚｚ FY2025 FY2024 1H 2H Full Year 1H 2H Full Year Net sales (JPY billion) 258.6 277.6 536.2 253.7 270.4 524.0 CONSOLIDATED Housing 167.1 174.9 342.0 165.2 172.2 337.3 Renovation 56.3 58.7 114.9 53.8 53.4 107.2 Residential 3
Slide 48: Various Performance Data
Various Performance Data Group-wide FY2025 FY2024 FY2023 FY2022 ■Net Sales (JPY billion) 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q HPP 108.2 115.3 114.2 118.8 110.6 110.5 112.0 114.2 96.1 104.2 106.0 106.6 99.1 102.4 97.9 97.0 Housing 128.4 130.3 136.4 141.2 116.2 137.4 132.0 138.4 121.0 143.8
Slide 49: Various Performance Data
Various Performance Data Industrial field FY2025 FY2024 FY2023 FY2022 ■Net Sales (JPY billion) 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q Labor-saving product 6.4 6.6 6.1 5.6 5.9 5.9 5.9 7.0 4.9 5.2 4.8 5.6 6.0 5.6 4.8 5.3 Environmentally friendly product 1.8 2.1 2.3 2.8 1.9 1.9 2.2 2.2 1.7 2.1
Slide 50: SEKISUI
SEKISUI Copyright® SEKISUI CHEMICAL CO., LTD.